bNAbs for HIV prevention: extended-release VRC01, AMP study, 10E8 safety signal and pan-clade challenges


The R4P2018 conference included a wealth of studies looking at broadly neutralising monoclonal antibody (bNAbs) for HIV prevention.

A selection of these studies reported below shows the complexities of this research which is important given large-scale studies are already ongoing.

New data on a long-acting variant of the bNAb VRC01 that requires less frequent infusions was included in several presentations.

This extended release formulation, VRC01-LS, has a two amino acid change that showed more durable protection against repeated SHIV challenges in animal studies.